Humoral immunotherapy of multiple myeloma: perspectives and perplexities

Bibliography

• Swerdlow SH. WHO Classification of Haematopoietic and Lymphoid tissue. 4th edition. WHO press, Geneva, Switzerland; 2008
   Google Scholar
• Singhal S, Mehta J, Desikan R, Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-71
   PubMed Web of Science ®Google Scholar
• Weber DM, Chen C, Niesvizky R, Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): results of a North American phase III study (MM-009). J Clin Oncol 2006;24: abstract 7521
   Web of Science ®Google Scholar
• Chang DH, Liu N, Klimek V, Enhancement of ligand dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 2006;108:618-21
   PubMed Web of Science ®Google Scholar
• Nencioni A, Grunebach F, Patrone F, Proteasome inhibitors: antitumor effects and beyond. Leukemia 2007;21:30-6
   PubMed Web of Science ®Google Scholar
• Lokhorst HM, Schattenberg A, Cornelissen JJ, Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol 2000;167:1212-21
   Google Scholar
• Crawley C, Iacobelli S, Bjorkstrand B, Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood 2007;109:3588-94
   PubMed Web of Science ®Google Scholar
• Rasmussen T, Hansson L, Österborg A, Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells. Blood 2003;101:4607-10
   PubMed Web of Science ®Google Scholar
• Yi Q, Freeman ME, Szmania S, Intranodal vaccination with idiotype-pulsed dendritic cells induces potent and long lasting cellular and humoral immune responses in myeloma patients. Blood 2003;102: abstract 5277
   Web of Science ®Google Scholar
• Stevenson FK, Ottensmeier CH, Johnson P, DNA vaccines to attack cancer. Proc Natl Acad Sci USA 2004;101:14646-52
   PubMed Web of Science ®Google Scholar
• Harrison SJ, Cook G. Immunotherapy in multiple myeloma–possibility or probability? Br J Haematol 2005;130:344-62
   PubMed Web of Science ®Google Scholar
• Houet L, Veelken H. Active immunotherapy of multiple myeloma. Eur J Cancer 2006;42:1653-60
   PubMed Web of Science ®Google Scholar
• Ansell SM, Armitage J. Non-Hodgkin lymphoma: diagnosis and treatment. Mayo Clin Proc 2005;80:1087-97
   PubMed Web of Science ®Google Scholar
• Cheson BD. Monoclonal antibody therapy for B-cell malignancies. Semin Oncol 2006;33:S2-14
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42
   PubMed Web of Science ®Google Scholar
• Cheson BD, Leonard JP. Monoclonal antibody therapy for non-Hodgkin's lymphoma. N Engl J Med 2008;359:613-26
   PubMed Web of Science ®Google Scholar
• Treon SP, Pilarski LM, Belch AR, CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. J Immunother 2002;25:72-81
   PubMed Web of Science ®Google Scholar
• Kapoor P, Greipp PT, Morice WG, Anti-CD20 monoclonal antibody therapy in multiple myeloma. Br J Haematol 2008;141:135-48
   PubMed Web of Science ®Google Scholar
• Ngo NT, Brodie C, Giles C, The significance of tumour cell immunophenotype in myeloma and its impact on clinical outcome. J Clin Pathol 2009;62:1009-15
   PubMed Web of Science ®Google Scholar
• Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 2004;103:2738-43
   PubMed Web of Science ®Google Scholar
• Gelderman KA, Tomlinson S, Ross GD, Gorter A. Complement function in mAb-mediated cancer immunotherapy. Trends Immunol 2004;25:158-64
   PubMed Web of Science ®Google Scholar
• Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003;22:7359-68
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Olejniczak S, Gowda A, Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin Cancer Res 2008;14:1561-70
   PubMed Web of Science ®Google Scholar
• Tomita A, Hiraga J, Kiyoi H, Epigenetic regulation of CD20 protein expression in a novel B-cell lymphoma cell line, RRBL1, established from a patient treated repeatedly with rituximab-containing chemotherapy. Int J Hematol 2007;86:49-57
   PubMed Web of Science ®Google Scholar
• Hiraga J, Tomita A, Sugimoto T, Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood 2009;113:4885-93
   PubMed Web of Science ®Google Scholar
• Sonoki T, Li Y, Miyanishi S, Establishment of a novel CD20 negative mature B-cell line, WILL2, from a CD20 positive diffuse large B-cell lymphoma patient treated with rituximab. Int J Hematol 2009;89:400-2
   PubMed Web of Science ®Google Scholar
• Jilani I, O'Brien S, Manshuri T, Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood 2003;102:3514-20
   PubMed Web of Science ®Google Scholar
• Terui Y, Mishima Y, Sugimura N, Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin's lymphoma. Clin Cancer Res 2009;15:2523-30
   PubMed Web of Science ®Google Scholar
• Lapalombella R, Yu B, Triantafillou G, Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells. Blood 2008;112:5180-9
   PubMed Web of Science ®Google Scholar
• Jazirehi AR, Vega MI, Bonavida B. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Res 2007;67:1270-1281
   PubMed Web of Science ®Google Scholar
• Bonavida B. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene 2007;26:3629-36
   PubMed Web of Science ®Google Scholar
• van Meerten T, van Rijn RS, Hol S, Complement induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clin Cancer Res 2006;12:4027-4035
   PubMed Web of Science ®Google Scholar
• Schonbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 2001;58:4-43
   PubMed Web of Science ®Google Scholar
• Banchereau J, Bazan F, Blanchard D, The CD40 antigen and its ligand. Annu Rev Immunol 1994;12:881-922
   PubMed Web of Science ®Google Scholar
• van Kooten C, Banchereau J. CD40–CD40 ligand. J Leukoc Biol 2000;67:2-17
   PubMed Web of Science ®Google Scholar
• Pluvinet R, Olivar R, Krupinski J, CD40: an upstream master switch for endothelial cell activation uncovered by RNAi-coupled transcriptional profiling. Blood 2008;112:3624-37
   Google Scholar
• Pellat-Deceunynck C, Bataille R, Robillard N, Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells. Blood 1994;84:2597-603
   PubMed Web of Science ®Google Scholar
• Tai YT, Podar K, Mitsiades N, CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-κB signaling. Blood 2003;101:2762-9
   PubMed Web of Science ®Google Scholar
• Tai YT, Podar K, Gupta D, CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells. Blood 2002;99:1419-27
   PubMed Web of Science ®Google Scholar
• Urashima M, Chauhan D, Hatziyanni M, CD40 ligand triggers interleukin-6 mediated B cell differentiation. Leuk Res 1996;20:507-15
   PubMed Web of Science ®Google Scholar
• Law CL, Gordon KA, Collier J, Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. Cancer Res 2005;65:8331-8
   PubMed Web of Science ®Google Scholar
• Tai YT, Catley LP, Mitsiades CS, Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer Res 2004;64:2846-52
   PubMed Web of Science ®Google Scholar
• Hayashi T, Treon SP, Hideshima T, Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells. Br J Haematol 2003;121:592-6
   PubMed Web of Science ®Google Scholar
• Tai YT, Li X, Tong X, Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. Cancer Res 2005;65:5898-906
   PubMed Web of Science ®Google Scholar
• Tai YT, Li XF, Catley L, Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. Cancer Res 2005;65:11712-20
   PubMed Web of Science ®Google Scholar
• Ocio EM, Mateos MV, Maiso P, New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. Lancet Oncol 2008;9:1157-65
   PubMed Web of Science ®Google Scholar
• Kastritis E, Charidimou A, Varkaris A, Targeted therapies in multiple myeloma. Targ Oncol 2009;4:23-36
   PubMed Web of Science ®Google Scholar
• Tai YT, Dillon M, Song W, Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 2008;112:1329-37
   PubMed Web of Science ®Google Scholar
• Tai YT, Soydan E, Song W, CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells. Blood 2009;113:4309-18
   PubMed Web of Science ®Google Scholar
• Hsi ED, Steinle R, Balasa B, CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res 2008;14:2775-84
   PubMed Web of Science ®Google Scholar
• Song W, Tai YT, Sasada T, Identification of CS1 peptides for induction of antigen specific CTLs in multiple myeloma. ASH Annual Meeting Abstracts 2007;110:1611
   Google Scholar
• Rice A, Dillon M, van Abbema A, Eradication of tumors in pre-clinical models of multiple myeloma by anti-CS1 monoclonal antibody HuLuc63: mechanism of action studies. ASH Annual Meeting Abstracts 2006;108:3503
   Google Scholar
• Bensinger W, Zonder J, Singhal S, Phase I trial of HuLuc63 in multiple myeloma. ASH Annual Meeting Abstracts 2007;110:1180
   Google Scholar
• Wijdenes J, Vooijs WC, Clement C, A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br J Haematol 1996;94:318-23
   PubMed Web of Science ®Google Scholar
• Tassone P, Goldmacher VS, Neri P, Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. Blood 2004;104:3688-96
   PubMed Web of Science ®Google Scholar
• Vooijs WC, Post J, Wijdenes J, Efficacy and toxicity of plasma-cell-reactive monoclonal antibodies B-B2 and B-B4 and their immunotoxins. Cancer Immunol Immunother 1996;42:319-28
   PubMed Web of Science ®Google Scholar
• Supiot S, Faivre-Chauvet A, Couturier O, Comparison of the biologic effects of MA5 and B-B4 monoclonal antibody labeled with iodine-131 and bismuth-213 on multiple myeloma. Cancer 2002;94:1202-9
   PubMed Web of Science ®Google Scholar
• Ikeda H, Hideshima T, Fulciniti M, The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res 2009;15:4028-37
   PubMed Web of Science ®Google Scholar
• Claesson L, Larhammer D, Rask L, Peterson PA. cDNA clone for the human invariant gamma chain of class II histo-compatibility antigens and its implications for the protein structure. Proc Natl Acad Sci USA 1983;80:7395-9
   PubMed Web of Science ®Google Scholar
• Morton PA, Zacheis ML, Giacoletto KS, Delivery of nascent MHC class II-invariant chain complexes to lysosomal compartments and proteolysis of invariant chain by cysteine proteases precedes peptide binding in B-lympho-blastoid cells. J Immunol 1995;154:137-50
   PubMed Web of Science ®Google Scholar
• Roche PA, Cresswell P. Intracellular transport of class II MHC molecules directed by invariant chain. Nature 1990;345:615-8
   PubMed Web of Science ®Google Scholar
• Roche PA, Teletski CL, Stang E, Cell surface HL A-DR-invariant chain complexes are targeted to endosomes by rapid internalization. Proc Natl Acad Sci USA 1993;90:8581-5
   PubMed Web of Science ®Google Scholar
• Starlets D, Gore Y, Binsky I, Cell surface CD74 initiates a signaling cascade leading to cell proliferation and survival. Blood 2006;107:4807-16
   PubMed Web of Science ®Google Scholar
• Beswick EJ, Pinchuk IV, Minch K, The Helicobacter pylori urease B subunit binds to CD74 on gastric epithelial cells and induces NF-κB activation and interleukin-8 production. Infect Immun 2006;74:1148-55
   PubMed Web of Science ®Google Scholar
• Leng L, Metz CN, Fang Y, MIF signal transduction initiated by binding to CD74. J Exp Med 2003;197:1467-76
   PubMed Web of Science ®Google Scholar
• Burton JD, Ely S, Reddy PK, CD74 is expressed by multiple myeloma and is a promising target for therapy. Clin Cancer Res 2004;10:6606-11
   PubMed Web of Science ®Google Scholar
• Stein R, Mattes MJ, Cardillo TM, CD74: a new candidate target for the immunotherapy of B-cell neoplasms. Clin Cancer Res 2007;13:5556-63
   PubMed Web of Science ®Google Scholar
• Stein R, Qu Z, Cardillo TM, Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies. Blood 2004;104:3705-11
   PubMed Web of Science ®Google Scholar
• Sapra P, Stein R, Pickett J, Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys. Clin Cancer Res 2005;11:5257-64
   PubMed Web of Science ®Google Scholar
• Moore KL, Eaton SE, Lyson DE, The P-selectin glycoprotein ligand from human neutrophils displays sialylated, fucosylated, O-linked poly-N-acetyllactosamine. J Biol Chem 1994;269:23318-27
   PubMed Web of Science ®Google Scholar
• Abbal C, Lambelet M, Berteggia D, Lipid raft adhesion receptors and Syk regulate selectin-dependent rolling under flow conditions. Blood 2006;108:3352-9
   PubMed Web of Science ®Google Scholar
• Jwa Hidari IP, Weyrich AS, Zimmermann GA, McEver RP. Engagement of P-selectin glycoprotein ligand-1 enhances tyrosine phosphorylation and activates mitogen-activated protein kinases in human neutrophils. J Biol Chem 1997;272:28750-6
   PubMed Web of Science ®Google Scholar
• Carlow DA, Gossens K, Naus S, PSGL-1 function in immunity and steady state homeostasis. Immunol Rev 2009;230:75-96
   PubMed Web of Science ®Google Scholar
• Evangelista V, Manarini S, Sideri R, Platelet/polymorphonuclear leukocyte interaction: P-selectin triggers protein-tyrosine phosphorylation-dependent CD11b/ CD18 adhesion: role of PSGL-1 as a signaling molecule. Blood 1999;93:876-85
   PubMed Web of Science ®Google Scholar
• Chen SC, Huang CC, Chien CL, Cross-linking of P-selectin glycoprotein ligand-1 induces death of activated T cells. Blood 2004;104:3233-42
   PubMed Web of Science ®Google Scholar
• Huang CC, Lu YF, Wen SN, A novel apoptosis-inducing anti-PSGL-1 antibody for T cell-mediated diseases. Eur J Immunol 2005;35:2239-49
   PubMed Web of Science ®Google Scholar
• Urzainqui A, Martínez del Hoyo G, Lamina A, Functional role of P-selectin glycoprotein ligand 1/P-selectin interaction in the generation of tolerogenic dendritic cells. J Immunol 2007;179:7457-65
   PubMed Web of Science ®Google Scholar
• Florena AM, Tripodo C, Miceli L, Identification of CD162 in plasma-cell dyscrasia. Lancet Oncol 2005;6:632
   PubMed Web of Science ®Google Scholar
• Tripodo C, Florena AM, Macor P, P-selectin glycoprotein ligand-1 as a potential target for humoral immunotherapy of multiple myeloma. Curr Cancer Drug Targets 2009;9:617-25
   PubMed Web of Science ®Google Scholar
• Yang J, Hirata T, Croce K, Targeted gene disruption demonstrates that P-selectin glycoprotein ligand 1 (PSGL1) is required for P-selectin-mediated but not E-selectin mediated neutrophil rolling and migration. J Exp Med 1999;190:1769-82
   PubMed Web of Science ®Google Scholar
• Bjorkman PJ, Burmeister WP. Structures of two classes of MHC molecules elucidated: crucial differences and similarities. Curr Opin Struct Biol 1994;4:852-6
   PubMed Web of Science ®Google Scholar
• Strominger JL. Human histocompatibility proteins. Immunol Rev 2002;185:69-77
   PubMed Web of Science ®Google Scholar
• Cooper EH, Plesner T. Beta-2-microglobulin review: its relevance in clinical oncology. Med Pediatr Oncol 1980;8:323-34
   PubMedGoogle Scholar
• Molica S, Levato D, Cascavilla N, Clinico-prognostic implications of simultaneous increased serum levels of solubile CD23 and beta2-microglobulin in B-cell chronic lymphocytic leukemia. Eur J Haematol 1999;62:117-22
   PubMed Web of Science ®Google Scholar
• Barlogie B, Jagannath S, Desikan KR, Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999;93:55-65
   PubMed Web of Science ®Google Scholar
• Yang J, Qian J, Wezeman M, Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies. Cancer Cell 2006;10:295-307
   PubMed Web of Science ®Google Scholar
• Yang J, Zhang X, Wang J, Anti beta2-microglobulin monoclonal antibodies induce apoptosis in myeloma cells by recruiting MHC class I to and excluding growth and survival cytokine receptors from lipid rafts. Blood 2007;110:3028-35
   PubMed Web of Science ®Google Scholar
• Fulciniti M, Hideshima T, Vermot-Desroches C, A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin Cancer Res 2009;15:7144-52
   PubMed Web of Science ®Google Scholar
• Voorhees PM, Chen Q, Small GW, Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death. Br J Haematol 2009;145:481-90
   PubMed Web of Science ®Google Scholar
• Neri P, Kumar S, Fulciniti MT, Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Clin Cancer Res 2007;13:5903-9
   PubMed Web of Science ®Google Scholar
• Tai YT, Li XF, Breitkreutz I, Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res 2006;66:6675-82
   PubMed Web of Science ®Google Scholar
• Rowinsky EK, Youssoufian H, Tonra JR, IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res 2007;13:5549s-55s
   PubMed Web of Science ®Google Scholar
• Raschko M, Markovina S, Miyamoto S, Phase II trial of bevacizumab combined with low dose dexamethasone and lenalidomide (BEV/REV/DEX) for relapsed or refractory myeloma (MM). ASH Annual Meeting Abstracts 2007;110:1173
   Google Scholar
• Shain KH, Yarde DN, Meads MB, beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. Cancer Res 2009;69:1009-15
   PubMed Web of Science ®Google Scholar
• Olson DL, Burkly LC, Leone DR, Anti-alpha4 integrin monoclonal antibody inhibits multiple myeloma growth in a murine model. Mol Cancer Ther 2005;4:91-9
   PubMed Web of Science ®Google Scholar
• Mori Y, Shimizu N, Dallas M, Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. Blood. 2004;104:2149-54
   PubMed Web of Science ®Google Scholar
• Gattei V, Bulian P, Del Principe MI, Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. Blood 2008;111:865-73
   PubMed Web of Science ®Google Scholar
• Shanafelt TD, Geyer SM, Bone ND, CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential. Br J Haematol 2008;140:537-46
   PubMed Web of Science ®Google Scholar
• Di Gaetano N, Cittera E, Nota R, Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 2003;171:1581-7
   PubMed Web of Science ®Google Scholar
• Macor P, Tedesco F. Complement as effector system in cancer immunotherapy. Immunol Lett 2007;111:6-13
   PubMed Web of Science ®Google Scholar